DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Rocha Lima CM, Green MR, Rotche R. et al.
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
J Clin Oncol 2004; 22: 3776-3783
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.